European research infrastructures join forces to provide innovative cancer research services across Europe—how can they support the cell and gene therapy developer?

E Oldoni, P Carvajal-Vallejos, F Bietrix et al

11 August 2023

Editorial

De-risking late-stage activities by retaining your early-stage expertise

Nolan Sutherland

28 August 2022

Editorial

Unproven stem cell-based interventions & harm to existing & future patients

Flora Naylor, Kirstin RW Matthews

27 March 2022

Editorial

Managing variability in autologous apheresis collections

Joseph Roig

22 February 2022

Editorial

Cell and gene therapy approvals soar in the first half of 2021

Christopher A Bravery

20 December 2021

Editorial

Biomanufacturing I-O therapeutics in the 21st century

Gregory Zarbis-Papastoitsis

29 November 2021

Editorial

A model for where we live

Jared Burks

25 November 2021

Editorial

Mass cytometry for comprehensive immune profiling in CAR T cell

Sneha Ramakrishna

18 November 2021

Editorial

Engineering new killers: bringing NK cells to the battle against cancer

Tamara J Laskowski, Sunil Acharya, Mayra Shanley

17 November 2021

Editorial

Full spectrum flow cytometry: a powerful cytometric analysis to benefit cell therapy

Ana Leda Figueiredo Longhini

10 November 2021

Editorial

Adherent versus suspension based platforms: what is the near future of viral vector manufacturing?

Ramin Baghirzade

09 November 2021

Editorial

Improving the yield of rAAV manufacturing with HeLa producer cells lines to ensure patient access

Matthew Fuller

05 October 2021

Editorial

CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

Lisa A Michaels, MD, Bruce E Eaton, PhD

05 August 2021

Editorial

Expanding gene therapy and gene editing strategies to large and complex indications

Carmen Unzu, Florie Borel

30 June 2021

Editorial

Alternative strategies for functionalizing CAR-T cells: engineering without genetic modification

Carolyn Porter

19 May 2021

Editorial

Outlook on manufacturing adoptive cell therapies for cancer immunotherapy

Xiuyan Wang, Isabelle Rivière

21 April 2021

Editorial

Considerations for controlling the variability of raw biological materials in the manufacturing of autologous patient-specific therapies

Sanjin Zvonic

16 March 2021

Editorial

Accelerating preclinical development for AAV based gene therapies: bridging the gap between discovery and clinical development

Louise Rodino-Klapac

24 February 2021

Editorial

Adherent systems for viral vector production

Hemant Dhamne, PhD

18 December 2020

Editorial

How to standardize quality requirements of raw materials

Bernd Leistler

01 December 2020

Editorial

Process development: how to win the race in cell & gene therapy

Ramin Baghirzade

04 November 2020

Editorial